Mlakar Vid, Berginc Gasper, Volavsek Metka, Stor Zdravko, Rems Miran, Glavac Damjan
Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
BMC Cancer. 2009 Aug 13;9:282. doi: 10.1186/1471-2407-9-282.
Despite identification of the major genes and pathways involved in the development of colorectal cancer (CRC), it has become obvious that several steps in these pathways might be bypassed by other as yet unknown genetic events that lead towards CRC. Therefore we wanted to improve our understanding of the genetic mechanisms of CRC development.
We used microarrays to identify novel genes involved in the development of CRC. Real time PCR was used for mRNA expression as well as to search for chromosomal abnormalities within candidate genes. The correlation between the expression obtained by real time PCR and the presence of the KRAS mutation was investigated.
We detected significant previously undescribed underexpression in CRC for genes SLC26A3, TPM1 and DCN, with a suggested tumour suppressor role. We also describe the correlation between TPM1 and DCN expression and the presence of KRAS mutations in CRC. When searching for chromosomal abnormalities, we found deletion of the TPM1 gene in one case of CRC, but no deletions of DCN and SLC26A3 were found.
Our study provides further evidence of decreased mRNA expression of three important tumour suppressor genes in cases of CRC, thus implicating them in the development of this type of cancer. Moreover, we found underexpression of the TPM1 gene in a case of CRCs without KRAS mutations, showing that TPM1 might serve as an alternative path of development of CRC. This downregulation could in some cases be mediated by deletion of the TPM1 gene. On the other hand, the correlation of DCN underexpression with the presence of KRAS mutations suggests that DCN expression is affected by the presence of activating KRAS mutations, lowering the amount of the important tumour suppressor protein decorin.
尽管已经确定了结直肠癌(CRC)发生过程中涉及的主要基因和信号通路,但很明显,这些通路中的几个步骤可能会被其他导致CRC的未知遗传事件所绕过。因此,我们希望增进对CRC发生遗传机制的理解。
我们使用微阵列来鉴定参与CRC发生的新基因。实时PCR用于mRNA表达分析以及寻找候选基因内的染色体异常。研究了实时PCR获得的表达与KRAS突变存在之间的相关性。
我们在CRC中检测到SLC26A3、TPM1和DCN基因存在显著的、此前未描述的低表达,提示它们具有肿瘤抑制作用。我们还描述了TPM1和DCN表达与CRC中KRAS突变存在之间的相关性。在寻找染色体异常时,我们在一例CRC中发现了TPM1基因的缺失,但未发现DCN和SLC26A3基因的缺失。
我们的研究进一步证明了在CRC病例中三个重要肿瘤抑制基因的mRNA表达降低,从而表明它们与这类癌症的发生有关。此外,我们在一例无KRAS突变的CRC中发现了TPM1基因的低表达,表明TPM1可能是CRC发生的另一条途径。这种下调在某些情况下可能是由TPM1基因的缺失介导的。另一方面,DCN低表达与KRAS突变存在之间的相关性表明,DCN表达受激活的KRAS突变影响,降低了重要肿瘤抑制蛋白核心蛋白聚糖的量。